VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the “Common Shares"), whi ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Gemini (GEMI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Gemini and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recogniz ...

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-grail-inc-investigation-gral.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 8 ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological c ...

GLEN BURNIE, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Glen Burnie Bancorp (“Company”) (OTCQX: GLBZ), the bank holding company for The Bank of Glen Burnie (“Bank”), announced today that current board member and local business leader, Jay Baldwin, has assumed the role of Chair of the Board of Directors effective immediately. Baldwin succeeds John “Jack” E. Demyan who announced his retirement at the February 19, 2026, meeting of the Glen Burnie Bancorp Board of Directors. Demyan retires after serving as Chair si ...

Kaldvik AS will publish its Q4 2025 quarterly update on 25 February 2026 at 07:00 CET. A webcast presentation of the Q4 2025 quarterly update will be held at 10:00 CET (09:00 Icelandic time) the same day. CEO Vidar Aspehaug and CFO Hjalti Hvítklett will present the Company’s results. The session will be held in English and conducted online. A Q&A session will follow the presentation. The webcast can be accessed via the following link: www.kaldvik.is/live Kaldvik AS publishes full financial statements semi-a ...

Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA. Attachment Notification of trade_skjema - Magnus Tolleshaug ...

Nanterre, 20 February 2026 VINCI enters into exclusive negotiations with the French government for the concession of the future A154 and A120 motorway link A major motorway project, spanning nearly 100 km, to enable traffic to bypass the Greater Paris area to the westA 35-year concession agreement, due to be signed in autumn 2026A project leveraging synergy between VINCI Concessions and VINCI Construction High environmental performance standards throughout the programme VINCI, through the consortium AREL, ...

Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to seek lead plaintiff status: April 6, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s drug, setrusumabInvestor action: Contact Kessler Topaz Meltzer & Check, LLP (www. ...

HOUSTON and LONDON, Feb. 20, 2026 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB), a leader in the global chemical industry, today announced that Agustin Izquierdo, executive vice president and chief financial officer, will participate in a fireside chat at the 2026 Bank of America Global Agriculture and Materials Conference in Fort Lauderdale, Fla., on Thursday, February 26, 2026, at 9:45 a.m. EST. Webcast and Presentation Slides AccessA live webcast can be accessed at the time of the event at https://inv ...